All moderate-dose statins protect the heart and brain equally well, even though some may slightly increase diabetes risk more than others.
Claim Context
The incidence of major adverse cardiac and cerebrovascular events is similar across all moderate-intensity statins in patients with established cardiovascular disease, indicating that differences in diabetes risk do not translate to differences in cardiovascular protection.
“In the moderate-intensity group... rosuvastatin, fluvastatin, pitavastatin, and pravastatin demonstrated comparable risks of MACCE (all p > 0.05), whereas simvastatin showed a modest but nonsignificant trend toward higher risk (adjusted HR 1.06, 95% CI 0.99–1.13; p = 0.11).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of RCTs could determine whether cardiovascular outcomes are truly equivalent across statins, regardless of diabetes risk differences.
A systematic review and meta-analysis of all randomized trials comparing moderate-intensity statins (atorvastatin, rosuvastatin, pravastatin, simvastatin) in secondary prevention, with MACCE as a primary outcome, including at least 50,000 participants and 3-year follow-up.
An RCT could determine whether switching statins affects cardiovascular outcomes independently of metabolic changes.
A double-blind RCT of 2,500 adults with ASCVD, randomized to moderate-intensity atorvastatin, rosuvastatin, pravastatin, or simvastatin for 4 years, with primary outcome being MACCE (MI, stroke, CV death) and secondary outcome being diabetes incidence.
A prospective cohort could confirm whether cardiovascular outcomes remain equivalent across statins after adjusting for unmeasured confounders like adherence and lifestyle.
A prospective cohort of 10,000 adults with ASCVD initiating moderate-intensity statins, with annual assessment of statin adherence, LDL-C levels, and cardiovascular events over 5 years, stratified by statin type.
A case-control study could identify whether patients who experience MACCE on one statin have distinct baseline characteristics compared to those on another.
A case-control study comparing 600 patients with MACCE on moderate-intensity statins to 600 matched controls without MACCE, assessing baseline statin type, LDL-C reduction, and metabolic markers.
A cross-sectional analysis could reveal whether statin type correlates with LDL-C levels or arterial plaque burden at a single time point.
A cross-sectional analysis of 8,000 adults with ASCVD on moderate-intensity statins, measuring LDL-C and carotid intima-media thickness via ultrasound at one visit, stratified by statin type.